Gaurav Parekh

Gaurav Parekh

Auto-generated profile, based on publicly available information

Gaurav Parekh

Glanbia Nutritionals Inc., Twin Falls, ID 83301, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2018 in Therapeutic Delivery
Verified
Journal Article
Open access
GPGaurav Parekh
Gaurav Parekh
YSYuanyuan Shi
Yuanyuan Shi
JZJuanjuan Zheng
Juanjuan Zheng
XZXingcai Zhang
Xingcai Zhang
Stefano LeporattiStefano Leporatti
Stefano Leporatti
Theranostic approaches using nanotechnology have been a hot research area for the past decade. All nano drug delivery techniques and architectures have some limitations, as do diagnostic nano-approaches. Thus, combining nano drug delivery strategies with diagnostic techniques using nanoparticles for improving imaging modalities has been the key to fill up those gaps. In the past decade, lots of approaches have been made with different combinations of biomaterials fabricated/synthesized to nanostructures with modified surface functionalization to improve their overall theranostic properties. This article summarizes recent research works based on the biomaterials used for fabricating these nanostructures. Their combinations with other biomaterials have been demonstrated with their overall advantages and limitations.

1 April 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
GPGaurav Parekh
Gaurav Parekh
PPPravin Pattekari
Pravin Pattekari
CJChaitanya Joshi
Chaitanya Joshi
TSTatsiana Shutava
Tatsiana Shutava
MDMark DeCoster
Mark DeCoster
YLYuri Lvov
Yuri Lvov

1 November 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
SMSamuel V. Mussi
Samuel V. Mussi
GPGaurav Parekh
Gaurav Parekh
PPPravin Pattekari
Pravin Pattekari
TLTatyana Levchenko
Tatyana Levchenko
YLYuri Lvov
Yuri Lvov
VTVladimir P. Torchilin
Vladimir P. Torchilin
A nanostructured lipid carrier (NLC) loaded with doxorubicin (DOX) has been shown to be cytotoxic against the human cancer cell lines A549 and MCF-7/Adr. In attempts to improve formulation characteristics, enhance pharmacokinetics and antitumor effects, we modified the surface of these NLC with an alternating layer-by-layer (LbL) assembly of polycation and polyanion polyelectrolytes and an additional coating with PEG using a simple method of core shell attachment. The formulation had a narrow size distribution, longer residence in the blood, lower accumulation in the liver, higher accumulation in tumors and a significant tumor growth inhibition effect. Thus, NLC-DOX nanopreparations complexes modified by LbL coating have the potential to enhance the anticancer effects of DOX against tumors.